To address this question, we selected the promoters, CTCF sites, and enhancers that were defined in normal cells (ChromHMM; HMEC and PrEC) and then characterized the epigenetic changes that occur at these precise genomic regions in cancer cells (MCF7 and PC3). This evidence concerns the gene CTCF and cancer.